Indication	Therapeutic Area	Sponsor	Protocol	Clinical Description
Attention Deficit Hyperactivity Disorder (ADH)	Child & Adolescent Psychiatry	Shire Development, LLC	SPD489-347	ADHD In Children Ages 4-5 years
Attention Deficit Hyperactivity Disorder (ADH)	Child & Adolescent Psychiatry	Shire Development, LLC	SPD489-348	Children Aged 4-5 Years Diagnosed with Attention-deficit/hyperactivity Diso
Attention Deficit Hyperactivity Disorder (ADH)	Child & Adolescent Psychiatry	Supernus Pharmaceuticals, Inc.	812P302	Evaluation of SPN-812 ER 200 and 400 mg Efficacy and Safety in Adolescents
Major Depressive Disorder	Child & Adolescent Psychiatry	Forest Research Institute	VLZ-MD-23	Vilazodone in Pediatric Patients With Major Depressive Disorder
Major Depressive Disorder	Neurology	Acadia Pharmaceuticals, Inc.	ACP-103-042	A Phase 2, Multicenter, Randomized, Double-blind, Placebocontrolled, Study
Major Depressive Disorder - Pediatric	Child & Adolescent Psychiatry	Forest Research Institute	VLZ-MD-22	Major Depressive Disorder
Schizophrenia	Psychiatry	Teva	TV46000-CNS-30072	Schizophrenia
Tourette's Disorder	Child & Adolescent Psychiatry	Neurocrine Biosciences	NBI-98854-TS2003	Treatment of Pediatric Subjects with Tourette Syndrome
Tourette's Disorder	Child & Adolescent Psychiatry	Nuvelution TS Pharma, Inc.	TVS0717-CNS-30047	Tourette Syndrome in Children and Adolescents
Tourette's Disorder	Child & Adolescent Psychiatry	Nuvelution TS Pharma, Inc.	TVS0717-CNS-30060	Tourette Syndrome in Children and Adolescents
Dementia with agitation	Adult Psychiatry	Acadia Pharmaceuticals, Inc.	ACP-103-046	Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurod
Dementia with Agitation	Adult Psychiatry	Acadia Pharmaceuticals, Inc.	ACP-103-047	Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurod
Borderline Personality Disorder	Adult Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	331-201-00242	Borderline Personality Disorder
Borderline Personality Disorder	Psychiatry	H. Lundbeck A/S	13546A	Major Depressive Disorder
pediatric depression	Psychiatry	H. Lundbeck A/S	13546A	Major Depressive Disorder
pediatric depression	Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	331-201-00195	Borderline Personality Disorder
Adult ADHD	Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	405-201-00016	Binge-Eating Disorder
Alzheimer's Disease	Adult Psychiatry	AZTherapies, Inc.	AZT-001	efficacy study of ALZT OP1 in subjects with evidence of early Alzheimer's d
Alzheimer's Disease	Adult Psychiatry	Neurim Pharmaceuticals Ltd.	NEUP11-A02	NEUP11-A02
Alzheimer's Disease	Adult Psychiatry	Otsuka Pharma Dev. & Com. Inc.	331-14-213	Alzheimer's Dementia
Alzheimer's Disease	Adult Psychiatry	Suven Life Sciences	225446	SUBJECTS WITH MODERATE ALZHEIMER'S DISEASE
Alzheimer's Disease	Adult Psychiatry	Tetra Discovery Partners	BPN14770-CNS-201	Early Stage Alzheimer's Disease
Alzheimer's Disease	Future Studies	Athira Pharma, Inc	ATH-1017-AD-0201	Mild to Moderate Alzheimer's
Alzheimer's Disease	Neurology	Athira Pharma, Inc	ATH-1017-AD-0203	Mild to Moderate Alzheimer's disease
Alzheimer's Disease	Neurology	Avanir Pharmaceuticals, Inc.	15-AVP-786-301	Treatment Of Agitation In Patients With Dementia Of The Alzheimer's Type
Alzheimer's Disease	Neurology	Avanir Pharmaceuticals, Inc.	Avanir 15-AVP-786-303	Treatment of Agitation in Patients with Dementia of the Alzheimer's Type
Alzheimer's Disease	Neurology	Avanir Pharmaceuticals, Inc.	17-AVP-786-305	Agitation in patients with Dementia of Alzheimer's Type
Alzheimer's Disease	Neurology	Axsome Therapeutics, Inc.	AXS-05-AD-303	Treatment of agitation associated with dementia of the Alzheimer's type
Alzheimer's Disease	Neurology	EIP Pharma, LLC	EIP-V017-745-304	Naflamajmod, Administered for 24 Weeks in Subjects with Mild Alzheimer's D
Alzheimer's Disease	Neurology	Neuraly, Inc.	NL101-AD-1	Mild Cognitive Impairment due to Alzheimer's Disease - Phase IIb
Alzheimer's Disease	Neurology	T3D Therapeutics, Inc	T3D959-202	Phase II, Double Blind, Placebo-Controlled, Multi-Center Study to Evaluate
Anxiety	Child & Adolescent Psychiatry	Allergan Sales, LLC	SCT-MD-60	Pediatric Generalized Anxiety Disorder
Anxiety	Future Studies	RealTime-CTMS	Future Studies	Future Studies
Anxiety	Neurology	Biohaven	BHV4157-301	A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of Trori
Anxiety	Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	405-201-00180	A Trial of Centanafadine Efficacy and Safety in Adults with ADHD and Comorb
Attention Deficit Hyperactivity Disorder (ADH)	Adult Psychiatry	Otsuka Pharma Dev. & Com. Inc.	405-201-00015	Open-label, 52-Week Tolerability of Centanafadine in Adults with ADHD
Attention Deficit Hyperactivity Disorder (ADH)	Adult Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	405-201-00014	Adult Attention-deficit/hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder (ADH)	Child & Adolescent Psychiatry	Supernus Pharmaceuticals, Inc.	812P301	Evaluation of SPN-812 ER 100 and 200mg Efficacy and Safety in Children with
Attention Deficit Hyperactivity Disorder (ADH)	Child & Adolescent Psychiatry	Supernus Pharmaceuticals, Inc.	812P310	ADHD
Attention Deficit Hyperactivity Disorder (ADH)	Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	405-201-00016	Adolescen Adolescents Attention-Deficit/Hyperactivity Disorder (ADHD)s Atte
Attention Deficit Hyperactivity Disorder (ADH)	Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	405-201-00017	Children and Adolescents with Attention-deficit/hyperactivity Disorder
Attention Deficit Hyperactivity Disorder (ADH)	Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	405-201-00021	Treatment of Children With Attention deficit/hyperactivity Disorder
Attention Deficit Hyperactivity Disorder (ADH)	Psychiatry	Supernus Pharmaceuticals, Inc.	812P401	ADHD
Autism Aggressive Behaviors	Neurology	Otsuka Pharmaceutical Development & Commercialization, Inc.	331-201-00148	Autism Spectrum Disorder
Autism Aggressive Behaviors	Pediatrics	Otsuka Pharmaceutical Development & Commercialization, Inc.	331-201-00191	Autism Spectrum Disorder
Back Pain	Pain Management / Anesthesiology	Neurana Pharmaceuticals, Inc	CLN-301	Pain Due to Acute Back Muscle Spasm
Binge Eating Disorder (BED)	Psychiatry	Sunovion Pharmaceuticals Inc.	SEP360-322	Binge Eating
Binge Eating Disorder (BED)	Psychiatry	Idorsia Pharmaceuticals,Inc.	ID-082A201	Binge Eating Disorder (BED) - Phase II
Binge Eating Disorder (BED)	Psychiatry	Sunovion Pharmaceuticals Inc.	SEP360-321	Binge Eating Disorder
Bipolar Depression	Psychiatry	Intra-Cellular Therapies, Inc. (ITI)	ITI-007-401	Monotherapy Treatment of MDD Patients w/ Bipolar Disorder
Bipolar Depression	Psychiatry	Intra-Cellular Therapies, Inc. (ITI)	ITI-007-402	Comparing Rx for Treating MD Episodes w/ Bipolar Disorder
Complex Regional Pain Syndrome type 1 (CRPS-1)	Pain Management / Anesthesiology	Grunenthal	KF7013-04	Complex Regional Pain Syndrom (CRPS)
pediatric depression	Psychiatry	Allergan Sales, LLC	LVM-MD-66	Constipation / IBS-C
Dementia	Neurology	Axsome Therapeutics, Inc.	AXS-05-AD-301	Addressing Dementia Via Agitation
Dementia	Neurology	Axsome Therapeutics, Inc.	AXS-05-AD-302	Dementia type of Alzheimer's - Phase III
Depression	Psychiatry	AbbVie, Inc.	M25-526	Subjects with Bipolar Disorder
Depression	Psychiatry	COMPASS Pathfinder Limited	COMP-006	COMP360 in participants with treatment-resistant depression
Depression	Psychiatry	Forest Research Institute	LVM-MD-11	Evaluation of the Safety and Efficacy of Levomilnacipran ER in Adolescent P
Depression	Psychiatry	Merck & Co.	MK-1942-006	Treatment Resistant Depression
Depression	Psychiatry	No Sponsor	MBM-002	Assessing Phenotype, risk factors and behaviors in Adults 18 and over with
Depression	Psychiatry	Sage Therapeutics, Inc.	217-PPD-201	Females with Postpartum Depression
Depression	Psychiatry	Sirtsel Pharmaceuticals, Inc.	SP-624-201	A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Sa
Fibromyalgia	Musculoskeletal	Aptinyx Inc.	NYX-2925-2005	A Randomized, Double-Blind, Placebo 'Controlled Study to Assess the Efficacy
General Anxiety Disorder	Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	SEP361-226	Adults with Generalized Anxiety Disorder
Major Depressive Disorder	Adult Psychiatry	Allergan Sales, LLC	1111-301-001	MAJOR DEPRESSIVE DISORDER
Major Depressive Disorder	Adult Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	382-201-00001	Major Depressive Disorder
Major Depressive Disorder	Child & Adolescent Psychiatry	Allergan Sales, LLC	2006-308-008	Major Depressive Disorder
Major Depressive Disorder	Child & Adolescent Psychiatry	H. Lundbeck A/S	12710A	fixed-dose study of vortioxetine in paediatric patients aged 7 to 11 years,
Major Depressive Disorder	Neurology	Allergan Sales, LLC	RAP-MD-04	A Randomized, Double blind, Placebo-controlled, Multicenter study of Rapast
Major Depressive Disorder	Neurology	Allergan Sales, LLC	RAP-MD-06	Long-term Safety Study of MDD
Major Depressive Disorder	Neurology	Allergan Sales, LLC	RAP-MD-02	Study of Rapastinel as Adjunctive Therapy in MDD
Major Depressive Disorder	Neurology	Allergan Sales, LLC	RAP-MD-03	Rapastinel as Adjunctive Therapy in Major Depressive Disorder
Major Depressive Disorder	Neurology	Intra-Cellular Therapies, Inc. (ITI)	ITI-007-505	Major Depressive Disorder
Major Depressive Disorder	Psychiatry	AbbVie, Inc.	M25-987	Major Depressive Disorder
Major Depressive Disorder	Psychiatry	Blackthorn Therapeutics, Inc.	K2-MDD-201	Major Depressive Disorder
Major Depressive Disorder	Psychiatry	Clexio Biosciences Limited	CLE100-MDD-201	Major Depressive Disorder
Major Depressive Disorder	Psychiatry	Clexio Biosciences Limited	CLE100-MDD-202	Major Depressive Disorder Patients with Inadequate Response to Standard Ant
Major Depressive Disorder	Psychiatry	Janssen R & D	67959964MDD3002	Major Depressive Disorder
Major Depressive Disorder	Psychiatry	Janssen R & D	67959964MDD3003	Major Depressive Disorder
Major Depressive Disorder	Psychiatry	LB Pharmaceuticals, Inc.	LB-102-011	Efficacy & Safety of LB-102 in the Treatment of Patients with MDD w/Bipolar
Major Depressive Disorder	Psychiatry	Neumora Therapeutics, Inc.	NMRA-335140-301	MDD
Major Depressive Disorder	Psychiatry	Neumora Therapeutics, Inc.	NMRA-335140-501	Major Depressive Disorder
Major Depressive Disorder	Psychiatry	Neumora Therapeutics, Inc.	NMRA-335140-303	Major Depressive Disorder
Major Depressive Disorder	Psychiatry	Neumora Therapeutics, Inc.	NMRA-335140 501	Safety and Effectiveness of NMRA-335140 in Participants with Major Depressi
Major Depressive Disorder	Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	405-201-00062	Major Depressive Disorder
Major Depressive Disorder	Psychiatry	Relmada Therapeutics, Inc.	REL-1017-304	Major Depressive Disorder
Major Depressive Disorder	Psychiatry	Takeda	LuAA21004_402	A Randomized, Double-Blind, Placebo-Controlled, Phase 4 Relapse Prevention
Major Depressive Disorder	Psychiatry	Xenon Pharmaceuticals	XPF-008-204	Major Depressive Disorder
Major Depressive Disorder - Pediatric	Child & Adolescent Psychiatry	H. Lundbeck A/S	12709A	Paediatric patients aged 7 to 11 years, with Major depressive disorder
Major Depressive Disorder - Pediatric	Psychiatry	H. Lundbeck A/S	13546A	Major Depressive Disorder
Migraine Headaches	Neurology	Satsuma Pharmaceuticals, Inc.	STS101-002	Acute Treatment of Migraine
Obsessive Compulsive Disorder (OCD)	Future Studies	Biohaven	BHV4157-209	A randomized, double-blind, placebo-controlled trial of adjunctive troriluz
Obsessive Compulsive Disorder (OCD)	Psychiatry	Biohaven	BHV4157- 302	Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Obsessive Compulsive Disorder (OCD)	Psychiatry	Biohaven	BHV4157-303	Obsessive Compulsive Disorder
Post Partum Depression	Adult Psychiatry	Sage Therapeutics, Inc.	217-PPD-301	Randomized, Double-Blind, Placebo-controlled Study Evaluating the Efficacy
Post Partum Depression	Psychiatry	Reunion Neurosciences	RE104-201-PPD	Patients with Postpartum Depression
Post Partum Depression	Psychiatry	Sage Therapeutics, Inc.	S47-PPD-404	PPD
Psychosis	Psychiatry	Acadia Pharmaceuticals, Inc.	ACP-103-045	Psychosis - Dementia Related
PTSD	Post-Traumatic Stress Disorder	Aptinyx Inc.	NYX-783-1004	Daily Doses of NYX-783 in Subjects with Post-Traumatic Stress Disorder
PTSD	Post-Traumatic Stress Disorder	Jazz Pharmaceuticals, Inc.	JZP150-201	Post-Traumatic Stress Disorder
PTSD	Psychiatry	Aptinyx Inc.	NYX-783-2009	Post Traumatic Stress Disorder
PTSD	Psychiatry	Otsuka Pharmaceutical Development & Commercialization, Inc.	331-201-00072	Brexpiprazole as Combination Therapy with Sertraline in Treatment of Adults
Schizophrenia	Adult Psychiatry	Boehringer Ingelheim	1289.49	Schizophrenia
Schizophrenia	Child & Adolescent Psychiatry	Allergan Sales, LLC	RGH-MD-20	Schizophrenia
Schizophrenia	Child & Adolescent Psychiatry	Allergan Sales, LLC	LVM-MD-14	Schizophrenia
Schizophrenia	Child & Adolescent Psychiatry	Otsuka Pharma Dev. & Com. Inc.	331-10-234	Adolescents (13-17 years old) With Schizophrenia
Schizophrenia	Child & Adolescent Psychiatry	Otsuka Pharma Dev. & Com. Inc.	331-10-236	Schizophrenia
Schizophrenia	Future Studies	Karuna Therapeutics, Inc.	KAR-011	DSM-5 Schizophrenia"
Schizophrenia	Neurology	Otsuka Pharmaceutical Development & Commercialization, Inc.	031-201-00301	A Phase IIb Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subject
Schizophrenia	Neurology	Teva Branded Pharmaceutical Products R&D, Inc.	TV46000-CNS-30078	to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Re
Schizophrenia	Psychiatry	Cerevel Therapeutics	CVL-231-2003	Adult Participants with Schizophrenia
Schizophrenia	Psychiatry	Concept Therapeutics, Inc	CORT18335-877	Obese Adults with Schizophrenia Taking Antipsychotic Medications
Schizophrenia	Psychiatry	Karuna Therapeutics, Inc.	KAR-012	Inadequately Controlled Symptoms of Schizophrenia
Schizophrenia	Psychiatry	Karuna Therapeutics, Inc.	KAR-013	Schizophrenia (OLE)
Schizophrenia	Psychiatry	Neurocrine Biosciences	NBI-1117568-SCZ3031	Efficacy of NBI-1117568 in Preventing Relapse of Symptoms of Schizophrenia
Schizophrenia	Psychiatry	Neurocrine Biosciences	NBI-1117568-SCZ3032	Safety and Tolerability of NBI-1117568 in Adults with Schizophrenia
Schizophrenia	Psychiatry	Recognify Life Sciences, Inc.	C07-03-02	Cognitive Impairment Associated with Schizophrenia (CIAS)
Social Anxiety Disorder	Psychiatry	EmpowerPharm, Inc.	EPI-CBD-001	Cannabidiol Oral Solution in Subjects with Social Anxiety Disorder
Tourette's Disorder	Psychiatry	Otsuka Pharma Dev. & Com. Inc.	31-14-204	Tourette's Disorder